Targeting CD133 reverses drug-resistance via the AKT/NF-κB/MDR1 pathway in colorectal cancer.
Yuan Z, Liang X, Zhan Y, Wang Z, Xu J, Qiu Y, Wang J, Cao Y, Le VM, Ly HT, Xu J, Li W, Yin P, Xu K.
Yuan Z, et al. Among authors: li w.
Br J Cancer. 2020 Apr;122(9):1342-1353. doi: 10.1038/s41416-020-0783-0. Epub 2020 Mar 16.
Br J Cancer. 2020.
PMID: 32203206
Free PMC article.